Telix announces Cardinal Health as U.S. commercial distributor for Zircaix
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2024
0mins
Partnership Announcement: Telix Pharmaceuticals has chosen Cardinal Health as the distributor for its PET1 agent, Zircaix, which is intended for kidney cancer imaging in the U.S., pending regulatory approval.
Distribution Agreement Details: The agreement will facilitate the availability of Zircaix across various U.S. locations and includes standard commercial performance and termination conditions, contingent on regulatory clearance.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAH is 225.18 USD with a low forecast of 209.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 206.890
Low
209.00
Averages
225.18
High
244.00
Current: 206.890
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
